Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting
Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting
July 1, 2024
Previous PostTeva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
Next PostH.C. Wainwright & Co. Initiates MedinCell’s Coverage with a “Buy” Recommendation
